文献速递乳腺癌放疗头颈部肿瘤放疗中枢神经肿瘤放疗

FLASH放疗治疗潜力探索:一项治疗计划研究

Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study.
PubMed 文献 · Radiother Oncol · 2025-05-21

本研究对每个瘤种5例患者(乳腺、头颈、前列腺、胶质母细胞瘤)进行计划分析,基于线性二次模型和临床前数据构建的剂量修饰因子模拟FLASH剂量分布,并转换为常规分割等效剂量比较正常组织损伤。乳腺和前列腺病例显示净保护为正,胶质母细胞瘤和头颈病例未观察到净保护。

要点

  • 乳腺和前列腺病例净保护为正,FLASH效应超过分割次数增加带来的毒性。
  • 胶质母细胞瘤和头颈病例未观察到净保护,即使考虑FLASH诱导的正常组织保护。
  • FLASH-RT可能对α/βT ≲ α/βNT的瘤种有益,需按瘤种考虑实施。

核心结论

  • FLASH-RT似乎对α/βT ≲ α/βNT的瘤种(如乳腺和前列腺)有益。
  • 并非所有瘤种都能从FLASH-RT获益,提示需按瘤种特异性考虑FLASH-RT实施。

研究设计与样本

  • 每个瘤种(乳腺、头颈、前列腺、胶质母细胞瘤)分析5例患者。
  • 使用线性二次模型从标准方案推导出更高分次剂量的剂量分布,同时保持肿瘤控制效能。
  • 基于临床前数据用逻辑回归构建剂量修饰因子,逐体素模拟FLASH修饰的剂量分布。
  • 将计划转换为常规分割等效剂量,进行正常组织损伤的放射生物学比较。
  • 净保护定义为标准和FLASH修饰计划之间OAR剂量体积直方图参数的差异,按处方剂量归一化。

主要发现

  • OAR和PTV的净保护因肿瘤部位差异很大。
  • 乳腺和前列腺病例显示净保护为正,表明FLASH效应超过增加的毒性。
  • 即使在保守场景(较高α/βT vs α/βNT)下,大多数OAR显示净保护为正。
  • 胶质母细胞瘤和头颈病例未观察到净保护,表明即使有FLASH诱导的正常组织保护,毒性仍增加。

关键数值与推荐

  • FLASH效应特别针对较大分次剂量(>5 Gy)。
  • 应用了肿瘤和晚反应正常组织常用的α/β比值。

临床怎么用

  • FLASH-RT的实施应考虑瘤种特异性,乳腺和前列腺可能获益而胶质母细胞瘤和头颈可能不获益。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/BACKGROUND: Ultra-high dose rate radiotherapy (RT) has shown potential for differential normal tissue (NT) sparing (a phenomenon termed the "FLASH effect"), particularly for larger fraction doses (>5 Gy). However, transitioning to hypofractionation may increase late-reacting NT toxicity, counteracting the FLASH effect. This study evaluates whether FLASH-RT can provide netsparing for organs at risk (OARs) and NT within the PTV under the assumption of standard-of-care dose-conformity. MATERIAL/METHODS: Five patients per tumor-site (breast, head-and-neck, prostate, and glioblastoma) were analyzed. Using the Linear-Quadratic model, dose-distributions with higher dose per fraction were derived from standard schedules while maintaining tumor control efficacy. FLASH-modified dose-distributions were simulated voxel-by-voxel using logistic regression-based dose-modifying factors modeled from preclinical data. These plans were converted to standard fractionation equivalents for radiobiological comparisons of NT damage. Netsparing was defined as the difference in OAR dose-volume histogram parameters between standard and FLASH-modified plans, normalized to the prescribed dose. Commonly used α/β-ratios for tumors and late-reacting NT were applied. RESULTS: The netsparing for OARs and PTV varied strongly by tumor location. Breast and prostate cases showed positive netsparing, indicating that the FLASH effect outweighed increased toxicity. Even under a conservative scenario (higher α/βT vs. α/βNT), most OARs showed positive netsparing. In glioblastoma and head-and-neck cases, no netsparing was observed, indicating increased toxicity even with FLASH induced NT-sparing. CONCLUSION: FLASH-RT appears to be beneficial for tumor sites where α/βT ≲ α/βNT, such as breast and prostate. However, not all tumor sites may benefit from FLASH-RT, highlighting the need for site-specific consideration for FLASH-RT implementation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Hörberger F, Petersson K, Ceberg S, et al. Investigating the therapeutic potential of FLASH radiotherapy - a treatment planning study. Radiother Oncol. 2025. PMID: 40409370. doi:10.1016/j.radonc.2025.110947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。